July 25, 2024

Eli Lilly’s Obesity Drug Success: Can the Surge Last?

Track all markets on TradingView Eli Lilly’s (NYSE:LLY) impressive market performance has raised eyebrows, propelled by its recently approved weight loss drug, Zepbound. The drugmaker unseated Tesla (NASDAQ: TSLA) from the “Magnificent 7” list of top-performing stocks in late January. Despite a slight dip, Lilly’s market capitalization remains formidable, hovering around $680 billion as of Eli Lilly’s Obesity Drug Success: Can the Surge Last?

The post Eli Lilly’s Obesity Drug Success: Can the Surge Last? appeared first on ImaStockTrader.

LATEST ARTICLES
ADVERTISING
RECOMMENDED

On this website we use first or third-party tools that store small files (cookie) on your device. Cookies are normally used to allow the site to run properly (technical cookies), to generate navigation usage reports (statistics cookies) and to suitable advertise our services/products (profiling cookies). We can directly use technical cookies, but you have the right to choose whether or not to enable statistical and profiling cookies. Enabling these cookies, you help us to offer you a better experience.